Two ongoing trials investigating ribociclib and one investigating abemaciclib as selective inhibitors of CDK4 and CDK6 are investigating the role of CDK inhibitors in treating meningiomas (NCT02933736, NCT03220646, NCT02523014). The gene discussed is CDK6; the disease is meningioma.